Tocilizumab in the treatment of coronavirus disease 2019 pneumonia: real-world data from a case series.

Cui, Ran; Zhu, Ying; Wang, Yulan; Chen, Xiao-Hua; Li, Qiang; Dai, Sheng-Ming; Tong, Qiang

Cui, Ran; Zhu, Ying; Wang, Yulan; Chen, Xiao-Hua; Li, Qiang; Dai, Sheng-Ming; Tong, Qiang.

Afiliação

Cui R; Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Zhu Y; Department of Infectious Diseases, Wuhan Leishenshan Hospital, Wuhan, Hubei, China.
Wang Y; Department of Respiratory & Critical Care Medicine, Seventh Medical Center of Chinese PLA General Hospital, Beijing, China.
Chen XH; Molecular Diagnostic Laboratory of Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li Q; Department of Infectious Diseases, Wuhan Leishenshan Hospital, Wuhan, Hubei, China.
Dai SM; Department of Infectious Diseases, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Tong Q; Department of Respiratory & Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medical, Shanghai, China.

Future Virol ; 2021 May.

Article em En | MEDLINE | ID: mdl-34055031

Palavras-chave

COVID-19; IL-6; IL-6 receptor; IL-6R antagonists; SARS-CoV-2; adverse events; cytokine release syndrome; inflammatory response; mortality; tocilizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Future Virol Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google